Free Trial

MeiraGTx Holdings plc (NASDAQ:MGTX) CFO Richard Giroux Sells 24,000 Shares

MeiraGTx logo with Medical background

MeiraGTx Holdings plc (NASDAQ:MGTX - Get Free Report) CFO Richard Giroux sold 24,000 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $6.29, for a total transaction of $150,960.00. Following the completion of the transaction, the chief financial officer now owns 849,947 shares of the company's stock, valued at $5,346,166.63. This trade represents a 2.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

MeiraGTx Price Performance

NASDAQ:MGTX traded up $0.15 during trading hours on Tuesday, reaching $6.41. 400,666 shares of the company's stock were exchanged, compared to its average volume of 327,372. The company has a market capitalization of $500.96 million, a P/E ratio of -5.30, a price-to-earnings-growth ratio of 0.34 and a beta of 1.26. MeiraGTx Holdings plc has a 12 month low of $3.85 and a 12 month high of $7.37. The company has a quick ratio of 2.34, a current ratio of 2.34 and a debt-to-equity ratio of 0.86. The business's 50-day simple moving average is $6.21 and its two-hundred day simple moving average is $5.25.

Institutional Trading of MeiraGTx

A number of large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC boosted its holdings in MeiraGTx by 13.3% during the fourth quarter. SG Americas Securities LLC now owns 22,240 shares of the company's stock worth $135,000 after buying an additional 2,617 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of MeiraGTx by 19.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 17,763 shares of the company's stock valued at $75,000 after purchasing an additional 2,839 shares during the period. JPMorgan Chase & Co. boosted its position in shares of MeiraGTx by 1.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 342,667 shares of the company's stock valued at $1,429,000 after purchasing an additional 4,186 shares during the period. Rhumbline Advisers boosted its position in shares of MeiraGTx by 10.8% in the 2nd quarter. Rhumbline Advisers now owns 52,996 shares of the company's stock valued at $223,000 after purchasing an additional 5,178 shares during the period. Finally, State Street Corp boosted its position in shares of MeiraGTx by 0.9% in the 3rd quarter. State Street Corp now owns 574,727 shares of the company's stock valued at $2,397,000 after purchasing an additional 5,251 shares during the period. 67.48% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Chardan Capital reiterated a "buy" rating and issued a $36.00 price objective on shares of MeiraGTx in a report on Monday, November 18th. Royal Bank of Canada raised their target price on MeiraGTx from $9.00 to $11.00 and gave the company an "outperform" rating in a research note on Thursday, November 14th.

Read Our Latest Analysis on MeiraGTx

About MeiraGTx

(Get Free Report)

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in MeiraGTx Right Now?

Before you consider MeiraGTx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MeiraGTx wasn't on the list.

While MeiraGTx currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Nuclear Energy’s Comeback: 7 Stocks to Watch in 2025

Nuclear Energy’s Comeback: 7 Stocks to Watch in 2025

Nuclear energy is making a resurgence! Watch to find out which seven nuclear energy stocks could deliver long-term gains in the transition to cleaner energy.

Related Videos

Pelosi Bets Big on AI: Her Top 5 Stock Picks
Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines